Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT04850235 Active, not recruiting - Clinical trials for Nasopharyngeal Cancer

Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study

Start date: April 15, 2021
Phase: Phase 1
Study type: Interventional

Neoadjuvant chemotherapy followed by concurrent chemoradiation (CCRT) has been recommended in the treatment of locoregionally-advanced nasopharyngeal carcinoma (NPC), with docetaxel, cisplatin (DDP) and 5-fluorouracil (5-Fu) shown to be an effective regimen. Capecitabine is the precursor drug of 5-fluorouracil, and has been used in replace of 5-fluorouracil in NPC patients. Nab-paclitaxel (Nab-PTX) is a novel albumin-bound paclitaxel with a superior therapeutic index to docetaxel. We sought to find out the efficacy of Nab-PTX in three-drug triplet (Nab-PTX, DDP and capecitabine) and decide the best administration dose of Nab-PTX.

NCT ID: NCT04586088 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Start date: May 5, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.

NCT ID: NCT04405622 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Start date: May 30, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT04398056 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to preliminarily evaluate the efficacy and safety of chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab for the de novo metastatic nasopharyngeal carcinoma.

NCT ID: NCT04384627 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy

NPC-GTV
Start date: December 1, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the long-term locoregional control, survival rate, late toxicity and quality of life after reducing the target volume in patients with locoregionally advanced nasopharyngeal carcinoma patients treated with induction chemotherapy plus concurrent chemoradiotherapy.

NCT ID: NCT04282070 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Start date: March 27, 2020
Phase: Phase 1
Study type: Interventional

This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).

NCT ID: NCT04272034 Active, not recruiting - Cervical Cancer Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Start date: March 26, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

NCT ID: NCT04242199 Active, not recruiting - Clinical trials for HepatoCellular Carcinoma

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Start date: September 4, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

NCT ID: NCT04223024 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Start date: December 12, 2019
Phase: Phase 2
Study type: Interventional

This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent chemoradiotherapy(CCRT) combined with nimotuzumab can improve the survival rate of high-risk patients and may provide new evidence for individualized comprehensive treatment of locally advanced NPC.

NCT ID: NCT04215978 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Start date: January 30, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.